About DrugAbuse Sciences
DrugAbuse Sciences is a company based in Menlo Park (United States) founded in 1994 was acquired by Elbion in January 2007. DrugAbuse Sciences offers products and services including Naltrexone Depot and Addiction Medications. DrugAbuse Sciences operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Drugabuse Sciences, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DrugAbuse Sciences
DrugAbuse Sciences offers a comprehensive portfolio of products and services, including Naltrexone Depot and Addiction Medications.
Injection for treating alcohol dependence and reducing cravings.
Develops drugs to address substance abuse disorders.
Funding Insights of DrugAbuse Sciences
Detailed funding history for DrugAbuse Sciences
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in DrugAbuse Sciences
DrugAbuse Sciences has secured backing from 1 investor. Prominent investors backing the company include Elbion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecules for CNS and inflammatory diseases were discovered.
|
Locked | Locked | Locked |
Investor details for DrugAbuse Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DrugAbuse Sciences
Investment portfolio details for DrugAbuse Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DrugAbuse Sciences
Detailed financials for DrugAbuse Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Drugabuse Sciences Comparisons
Peer comparison for DrugAbuse Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DrugAbuse Sciences
DrugAbuse Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for addictive and eating disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for substance use disorders are developed by Amygdala Neurosciences.
|
Detailed competitors of DrugAbuse Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Drugabuse Sciences
Complete news archive for DrugAbuse Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DrugAbuse Sciences
DrugAbuse Sciences was founded in 1994.
DrugAbuse Sciences is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
DrugAbuse Sciences was founded in 1994 in Menlo Park, United States, as a specialty pharmaceutical company focused on addiction treatments. Therapies targeting alcohol, opiate, cocaine, and heroin dependencies are developed and commercialized. Key products include Naltrexone Depot for alcohol and opiate addictions, DAS-431 for cocaine addiction, and Buprenorphine for heroin and opiate use. Company assets were acquired by Elbion in January 2007, now integrated into Biotie.
DrugAbuse Sciences's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
DrugAbuse Sciences offers Naltrexone Depot and Addiction Medications.
DrugAbuse Sciences has 1 investor. Key investors include Elbion.